vs
Side-by-side financial comparison of LEE ENTERPRISES, Inc (LEE) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $130.1M, roughly 1.4× LEE ENTERPRISES, Inc). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -4.3%, a 6.0% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -10.0%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -5.8%).
Lee Enterprises, Inc. is a publicly traded American media company. It publishes 72 daily newspapers in 25 states, and more than 350 weekly, classified, and specialty publications. Lee Enterprises was founded in 1890 by Alfred Wilson Lee and is based in Davenport, Iowa.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
LEE vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $130.1M | $177.4M |
| Net Profit | $-5.6M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | 4.0% | 3.9% |
| Net Margin | -4.3% | 1.6% |
| Revenue YoY | -10.0% | 5.0% |
| Net Profit YoY | 66.5% | — |
| EPS (diluted) | $-0.92 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $130.1M | $196.9M | ||
| Q3 25 | $139.1M | $179.5M | ||
| Q2 25 | $141.3M | $181.1M | ||
| Q1 25 | $137.4M | $168.9M | ||
| Q4 24 | $144.6M | $187.3M | ||
| Q3 24 | $158.6M | $168.6M | ||
| Q2 24 | $150.6M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-5.6M | — | ||
| Q3 25 | $-6.4M | $5.4M | ||
| Q2 25 | $-1.9M | $-4.8M | ||
| Q1 25 | $-12.5M | $4.8M | ||
| Q4 24 | $-16.7M | — | ||
| Q3 24 | $-10.1M | $-143.5M | ||
| Q2 24 | $-4.3M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 4.0% | 1.2% | ||
| Q3 25 | -1.0% | 3.5% | ||
| Q2 25 | 3.3% | 4.7% | ||
| Q1 25 | -3.3% | 1.2% | ||
| Q4 24 | -2.3% | 13.2% | ||
| Q3 24 | -2.3% | -82.8% | ||
| Q2 24 | 3.3% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | -4.3% | — | ||
| Q3 25 | -4.6% | 3.0% | ||
| Q2 25 | -1.4% | -2.7% | ||
| Q1 25 | -9.1% | 2.8% | ||
| Q4 24 | -11.6% | — | ||
| Q3 24 | -6.4% | -85.1% | ||
| Q2 24 | -2.8% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-0.92 | $0.05 | ||
| Q3 25 | $-1.02 | $0.12 | ||
| Q2 25 | $-0.31 | $-0.11 | ||
| Q1 25 | $-2.07 | $0.10 | ||
| Q4 24 | $-2.80 | $0.38 | ||
| Q3 24 | $-1.68 | $-3.11 | ||
| Q2 24 | $-0.73 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $12.6M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-48.7M | $653.9M |
| Total Assets | $592.6M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $12.6M | $238.4M | ||
| Q3 25 | $10.0M | $246.3M | ||
| Q2 25 | $14.1M | $445.9M | ||
| Q1 25 | $4.7M | $493.6M | ||
| Q4 24 | $6.1M | $484.6M | ||
| Q3 24 | $9.6M | $453.8M | ||
| Q2 24 | $13.4M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $-48.7M | $693.1M | ||
| Q3 25 | $-43.3M | $727.2M | ||
| Q2 25 | $-40.5M | $757.8M | ||
| Q1 25 | $-38.9M | $798.5M | ||
| Q4 24 | $-26.7M | $778.3M | ||
| Q3 24 | $-9.9M | $749.6M | ||
| Q2 24 | $4.0M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $592.6M | $1.3B | ||
| Q3 25 | $601.7M | $1.3B | ||
| Q2 25 | $622.7M | $1.5B | ||
| Q1 25 | $623.9M | $1.6B | ||
| Q4 24 | $633.0M | $1.6B | ||
| Q3 24 | $649.2M | $1.5B | ||
| Q2 24 | $677.5M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.5M | — |
| Free Cash FlowOCF − Capex | $3.7M | — |
| FCF MarginFCF / Revenue | 2.9% | — |
| Capex IntensityCapex / Revenue | 0.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $4.5M | $43.7M | ||
| Q3 25 | $-6.3M | $60.8M | ||
| Q2 25 | $8.9M | $12.0M | ||
| Q1 25 | $-790.0K | $35.5M | ||
| Q4 24 | $-7.3M | $33.1M | ||
| Q3 24 | $-261.0K | $53.9M | ||
| Q2 24 | $-1.9M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $3.7M | $43.5M | ||
| Q3 25 | $-8.3M | $57.0M | ||
| Q2 25 | $8.3M | $9.3M | ||
| Q1 25 | $-2.2M | $26.9M | ||
| Q4 24 | $-8.9M | $31.0M | ||
| Q3 24 | $-2.9M | $49.8M | ||
| Q2 24 | $-5.5M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 2.9% | 22.1% | ||
| Q3 25 | -6.0% | 31.7% | ||
| Q2 25 | 5.9% | 5.1% | ||
| Q1 25 | -1.6% | 15.9% | ||
| Q4 24 | -6.1% | 16.6% | ||
| Q3 24 | -1.8% | 29.6% | ||
| Q2 24 | -3.6% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.6% | 0.1% | ||
| Q3 25 | 1.4% | 2.2% | ||
| Q2 25 | 0.4% | 1.5% | ||
| Q1 25 | 1.0% | 5.1% | ||
| Q4 24 | 1.1% | 1.1% | ||
| Q3 24 | 1.7% | 2.4% | ||
| Q2 24 | 2.4% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LEE
| Advertising And Marketing Services | $60.0M | 46% |
| Subscription And Circulation | $57.7M | 44% |
| Other | $12.4M | 10% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
